Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|April 20, 2020
Ripple Science Announces Initiatives During COVID-19
Advertisement
Ripple Science has announced new initiatives to help clinical researchers continue their work through COVID-19. Many clinical trial teams are working remotely and have paused patient visits, forcing teams to do more of their work online. Ripple Science wants to help researchers continue their research during this uncertain time by giving research teams free access to Ripple for their first study. For those working on COVID-19 trials directly, the company is providing six-months of access to Ripple free of charge.
Ripple is a web-based platform designed for clinical research teams who want a secure and streamlined way to recruit, manage, and retain patients for trials. Ripple is a purpose-built CRM and project manager which organizes clinical trial recruiting and research efforts. Debi Gross, Community Outreach Director for Stony Brook University’s autism initiative, stated, “The fact that Ripple is web-based is a game-changer for us...The time between when participants contact us to enrolling them in a study seems a lot shorter and quicker.”
Peter Falzon, President and CEO of Ripple Science, commented, "We are committed to supporting research teams to work remotely and communicate with patients differently in response to COVID-19. Our customers have been telling us what they need and how Ripple helps, and we are responding to their needs by accelerating feature updates and expanding access.”
In the upcoming weeks, Ripple Science will release features aligned to even better support the initiatives of researchers working in this new paradigm.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
3
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
4
Where AI Governance in Clinical Development Falls Short
5